New drug OMO-103 tested in early pancreatic cancer trial
NCT ID NCT07089940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the drug changes the tumor's biology by analyzing tissue samples before and after treatment. This study does not aim to cure or control the disease directly, but to gather important information about how the drug works in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- Smart drug delivers chemo directly to pancreatic cancer cells
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer